- Companies
- GIMV
GIMV Valuation Multiples
GIMV is valued at $2B as of October 2026, a 6.3x revenue multiple. In the last fiscal year, GIMV revenue was $352M.
GIMV Overview
About GIMV
GIMV NV is a Belgium-based company active in investing in companies having growth potential, with the objective of supporting growth into market leaders. The company invests with a focus on four platforms, which are also its segments: Consumer, Healthcare, Life Sciences, Smart Industries, Anchor, Infra, Business Services & General segment, and Sustainable Cities. Its geographical segments include Belgium, the Netherlands, Germany, France, and the Rest of Europe and Other countries.
Founded
1980
HQ
Employees
17.4K
Website
Sectors
Financials (Last FY)
EV
$2.2B
Valuation Multiples
Start free trialGIMV Financials
GIMV reported last fiscal year revenue of $352M.
In the same fiscal year, GIMV generated $246M in net income.
GIMV P&L
In the most recent fiscal year, GIMV reported revenue of $352M and net income of $246M.
GIMV is profitable as of last fiscal year, with net margin of 70%.
Financial data powered by Morningstar, Inc.
GIMV Stock Performance
GIMV has current market cap of $2B, and enterprise value of $2.2B.
Market Cap Evolution
GIMV's stock price is $53.51.
GIMV share price increased by 1.1% in the last 30 days, and decreased by 1.4% in the last year.
GIMV has an EPS (earnings per share) of $6.68.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.2B | $2B | 0.0% | 1.1% | 3.8% | -1.4% | $6.68 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGIMV Valuation Multiples
GIMV trades at 6.3x EV/Revenue multiple.
GIMV Financial Valuation Multiples
As of October 18, 2026, GIMV has market cap of $2B and EV of $2.2B.
GIMV has a P/E ratio of 8.0x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified GIMV Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


GIMV Margins & Growth Rates
In the most recent fiscal year, GIMV reported net margin of 70%.
GIMV Margins
GIMV Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
GIMV Operational KPIs
GIMV's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
GIMV Competitors
GIMV competitors include Kinnevik, China-Singapore Suzhou, Bure Equity, Georgia Capital, HgCapital, Fairfax India Holdings, Molten Ventures, Antin Infrastructure Partners, InvestCo Holding and Ninety One.
Most GIMV public comparables operate across PE & VC.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| ($387M) | ($512M) | (5.2x) | - | (3.9x) | (21.8x) | |||
| $481M | $332M | 7.0x | 7.1x | 10.1x | 11.8x | |||
| $27M | ($470M) | 79.5x | - | (4.6x) | - | |||
| $733M | - | 2.3x | - | - | - | |||
| $148M | - | 15.2x | - | - | - | |||
| $609M | - | 3.8x | - | - | - | |||
| $200M | $178M | 8.0x | 4.9x | 9.0x | 5.3x | |||
| $328M | $185M | 3.6x | 3.6x | 6.4x | 6.9x | |||
This data is available for Pro users. Sign up to see all GIMV competitors and their valuation data. Start Free Trial | ||||||||
Acquisitions by GIMV
GIMV has acquired 67 companies to date.
Last acquisition by GIMV was on June 24th 2026. GIMV acquired The Cap Vert Development Group for $314M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by GIMV
| Description | The Cap Vert Development Group is a landscaping firm delivering comprehensive green space services across France, including landscape design, pruning, irrigation systems, fountain installation, and ongoing maintenance for public parks and private gardens. Paris-based with operations nationwide, the company manages over 5,000 sites for municipal governments and commercial clients like luxury hotels in Provence. Founded in 2005, it employs specialized teams for biodiversity enhancement projects using native plants in regions such as Normandy and the French Riviera. Recent contracts involve restoring historic gardens at Versailles and developing urban green roofs in Lyon. | Hemink Groep is a Dutch property service provider headquartered in Deventer delivering maintenance, renovation, and complete outfitting for residential and commercial buildings. The company handles electrical installations, HVAC systems, plumbing, and painting projects across the Netherlands. With a workforce specialized in multi-trade execution, Hemink Groep manages turnkey projects from initial assessment to final handover. Serving housing associations, property developers, and corporate clients, the firm emphasizes sustainable building practices and compliance with Dutch building codes. | Alpine Hearing Protection is a Netherlands-based manufacturer of custom-fit earplugs for musicians, motorsport enthusiasts, and industrial workers. Its product line includes models like MusicSafe, MotoSafe, and WorkSafe, sold through retailers in Europe and beyond. | - | |
| HQ Country | |||||
| HQ City | Paris | Enschede | Utrecht | Amsterdam | |
| Deal Date | 24 Jun 2026 | 22 Jul 2025 | 24 Jun 2025 | 27 May 2025 | |
| Valuation | $314M | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all GIMV acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by GIMV
GIMV has invested in 65 companies to date.
Latest investment by GIMV was on April 30th 2026. GIMV invested in Azelis Group in their Secondary round.
Latest Investments by GIMV
| Description | Azelis Group NV is a Belgium-based distributor of specialty chemicals and food ingredients. The Company focuses on the intensified efforts for formulation work and application that supports the partners from the labs. It works with Business to Business (B2B) buyers in the digital tools investment and technologies using online portals to find information on sellers, products, and services. The company has its business operating segments namely EMEA includes all operating companies in Europe, Middle East and Africa, Americas includes all operating companies in the United States of America, Canada, Mexico and South America (mainly Colombia and Brazil). Asia-Pacific involves all operating companies in Asia, South-East Asia and the Pacific region. | Exciva is a Heidelberg-based provider of targeted drug rescue programs for pharmaceutical research and development. The company develops symptomatic and disease-modifying treatments by repurposing approved drugs for new indications, including therapies, cures, prophylactics, supplements, and formulations. These efforts support healthcare organizations in rescuing and reusing existing drugs through specialized methods of production and application. | Kinaset Therapeutics is a Melbourne-headquartered clinical-stage company developing inhaled therapeutics for respiratory diseases. Its lead asset KIN-301 targets idiopathic pulmonary fibrosis with Phase 1 data showing safety in 50 patients. The pipeline includes candidates for COPD and asthma, licensed from Monash University research. | Equine Care Group is a Belgian veterinary group specialising in equine medicine. It was created in 2021 by merging Tom Marien's EquiTom clinic with Global Medics and Frederik Bruyninx's ambulatory practice, and has grown into a network of clinics and ambulatory services aimed at becoming a one-stop partner for high-quality horse medicine. Its shareholder base brings together the founding veterinarians, their managers and outside investors. | |
| HQ Country | |||||
| HQ City | Toronto | Heidelberg | Boston, MA | - | |
| Deal Date | 30 Apr 2026 | 20 Jan 2026 | 10 Jan 2026 | 27 Nov 2025 | |
| Round | Secondary | Series B | Series B | Undisclosed stage | |
| Raised | undisclosed | $60M | $103M | undisclosed | |
| Investors | WorxInvest; GIMV | LBBW VC; EQT; GIMV; LifeArc Ventures; Andera Partners; Fountain Healthcare Partners; Carma Fund; Modi Ventures | Willett Advisors LLC; 5AM Ventures; Sixty Degree Capital; EQT; Forge Life Science Partners; Atlas Venture; GIMV; Vivo Capital; RA Capital Management; Pictet Alternative Advisors; Schroders Capital | Bencis Capital Partners; GIMV | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all GIMV investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout GIMV
| When was GIMV founded? | GIMV was founded in 1980. |
| Where is GIMV headquartered? | GIMV is headquartered in Belgium. |
| How many employees does GIMV have? | As of today, GIMV has over 17K employees. |
| Who is the CEO of GIMV? | GIMV's CEO is Koen Dejonckheere. |
| Is GIMV publicly listed? | Yes, GIMV is a public company listed on Euronext Brussels. |
| What is the stock symbol of GIMV? | GIMV trades under GIMB ticker. |
| When did GIMV go public? | GIMV went public in 1997. |
| Who are competitors of GIMV? | GIMV main competitors include Kinnevik, China-Singapore Suzhou, Bure Equity, Georgia Capital, HgCapital, Fairfax India Holdings, Molten Ventures, Antin Infrastructure Partners, InvestCo Holding, Ninety One. |
| What is the current market cap of GIMV? | GIMV's current market cap is $2B. |
| What is the current revenue of GIMV? | GIMV's last fiscal year revenue is $352M. |
| What is the current EV/Revenue multiple of GIMV? | Current revenue multiple of GIMV is 6.3x. |
| Is GIMV profitable? | No, GIMV is not profitable. |
| How many companies GIMV has acquired to date? | As of October 2026, GIMV has acquired 60 companies. |
| What was the largest acquisition by GIMV? | $314M acquisition of The Cap Vert Development Group on 24th June 2026 was the largest M&A GIMV has done to date. |
| What companies GIMV acquired? | GIMV acquired The Cap Vert Development Group, Smart Battery Solutions, Acceo, United Dutch Breweries, MVZ Holding, Kind Technologies, Europlasma, AME, Biolam, Summa, and 50 other companies. |
| In how many companies GIMV has invested to date? | As of October 2026, GIMV has invested in 65 companies. |
| What was the last GIMV investment? | On 30th April 2026 GIMV invested in Azelis Group, participating in a Secondary round, alongside WorxInvest. |
| In what companies GIMV invested in? | GIMV invested in Kinaset Therapeutics, JenaValve Technology, Kivu Bioscience, Precirix, Mediar Therapeutics, Complement Therapeutics, ImmunOs Therapeutics, Covagen, Exciva, Anjarium Biosciences, Almaviva Santé, ImCheck Therapeutics, Lampiris, FIRE1, Breath Therapeutics, SynOx Therapeutics, iSTAR Medical, Endosense, Biotalys, Biom'Up, and 45 other companies. |
See public comps similar to GIMV
Lists including GIMV
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




